Vimarsana
Biggest News Aggregation in the World

Page 29 - Current Report News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Current Report. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Current Report Today - Breaking & Trending Today

Masonite Shareholders Approve Transaction with Owens Corning - Vimarsana News

Masonite Shareholders Approve Transaction with Owens Corning

Masonite International Corporation today announced that its shareholders have voted to approve the Company’s proposed transaction with Owens Corning at its Special Meeting of Shareholders. As...

Primis Financial Corp. Reports Preliminary Earnings Per Share for the First Quarter of 2024 - Vimarsana News

Primis Financial Corp. Reports Preliminary Earnings Per Share for the First Quarter of 2024

/PRNewswire/ -- Primis Financial Corp. (NASDAQ: FRST) ("Primis" or the "Company"), and its wholly-owned subsidiary, Primis Bank (the "Bank"), today reported...

Universal Display : 2024 Notice of Annual Meeting and Proxy Statement - Vimarsana News

Universal Display : 2024 Notice of Annual Meeting and Proxy Statement

UNIVERSAL DISPLAY CORPORATION 250 Phillips Boulevard Ewing, New Jersey 08618 NOTICE OF 2024 ANNUAL MEETING OF...

Surgery Partners : 2024 Proxy Statement - MarketScreener - Vimarsana News

Surgery Partners : 2024 Proxy Statement - MarketScreener

Notice of 2024 Annual Meeting and Proxy Statement April 25, 2024 TO OUR STOCKHOLDERS: ...

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update - Vimarsana News

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee o

Source: yahoo.com